Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT03864042
- Locations
- 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03806101
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 134
- Registration Number
- NCT03801733
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Québec City, Quebec, Canada
Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 80
- Registration Number
- NCT03720067
- Locations
- 🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the Elderly
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03715101
Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT03699774
- Locations
- 🇺🇸
Worldwide Clinical Trials (WCT) Early Phase Services, San Antonio, Texas, United States
"Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects"
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Dr. D. Y. Patil Dental College & Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03677297
- Locations
- 🇮🇳
Sukhada Deo, Pune, Maharashtra, India
Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 134
- Registration Number
- NCT03566316
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2018-05-29
- Target Recruit Count
- 150
- Registration Number
- NCT03521700
- Locations
- 🇨🇳
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
- Conditions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 317
- Registration Number
- NCT03516955
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.